prevalent with the chromatographic techniques. The finding concerning the BCL opiates test therefore appears sound but those relating to TLC require more accurate quantification.
Sensitivity and specificity of the available analytical techniques are factors to be taken into account in setting desirable standards of performance for drug assays (3). However, the clinical context of measurements is of overriding importance. The question posed is generally not whether the subject has abused drugs at some unspecified time in the past but, more typically, has a nonprescribed compound been taken within the last 24 to 72 h? Threshold concentrations are therefore greater than those applied in the field of employee screening (4) , though the consequences of analytical errors are no less serious in the damage they may cause the patient; therefore, the standards of specificity should be equally demanding in both contexts.
These data demonstrated that laboratories did not always achieve the goal of easily confirming the presence of an analyte by the use of two techniques based on different physicochemical principles. Because the concentration ranges chosen for the present study were thought appropriate to the clinical field, and because increasing thresholds above these values would be un-CLIN.CHEM.37/3, 447-451 (1991) realistic, we conclude that the use of certain techniques is inappropriate for some analytes. For patients with symptoms of pancreatitis, measurement of amylase in serum reportedly is more sensitive than that of lipase in acute pancreatitis, whereas lipase reportedly is more specific. However, serum lipase activities exceeding the upper reference limit (URL) have been reported for many patients who did not have pancreatitis. I reviewed the serum lipase and amylase concentrations of 493 consecutive inpatients and emergency department patients for whom both tests were ordered. Serum lipase and amylase activities, determined with an Ektachem 700 analyzer, were URL for 390 patients (83%) and >URL for 103. Medical records of 101 of these 103 were reviewed; 18 had acute or chronic relapsing pancreatitis. In this latter group, serum lipase values >URL had 100% sensitivity and 84% specificity; those of serum amylase >URL had 72% sensitivity and 88% specificity. However, the test combination 
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Received May 25, 1990 ; accepted November 7, 1990. of serum lipase >URL and serum amylase URL also occurred in 84% of the patients in which review of the medicalrecords revealed nonpancreatic gastrointestinal or hepatobiliary disorders as the primary problem (n = 55).
Therefore, serum lipase activity measured with the Ektachem assay is also often increased in patients with intra-abdominal disorders that appear to be nonpancreatic.
Triacylglycerol lipase (EC 3.1.1.3) and a-amylase (EC 3.2.1.1) activities in serum are most commonly used as aids in the differential diagnosis of pancreatitis. Measures of both enzymes reportedly have approximately equal sensitivities for detecting acute pancreatitis, with those of lipase having greater specificity (1) (2) (3) (4) (5) (6) . Although recent publications indicate that measuring serum lipase alone has high sensitivity ( 93%) and specificity (>90%) for detecting acute pancreatitis (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , a study that examined two methods for serum lipase showed low specificities (26% and 32%) (17) .
Lipase is also present in organs other than the pancreas (2-4, 7, 18-22) . Most nonpancreatic serum lipase involve use of antibodies to human pancreatic lipase (8, 24) , with specificity for pancreatic lipase said to be greater than that of other methods. Although some investigators have suggested ways to optimize the response of nephelometric lipase assays to the pancreatic form of lipase (18, 20) ,! found no published comparisons in the recent literature of the responsivities of various lipase assays to the intestinal and pancreatic forms. In our hospital, serum lipase activities exceeding the upper reference limit (URL) were reported for many patients who did not have pancreatitis, leading clinicians to believe that our reference limits were incorrect. ' In a retrospective clinical study, I investigated the Ektachem assay of lipase to determine its specificity for pancreatic lipase.
I also undertook a brief experiment to determine the response of the Ektachem lipase assay to esterase (carboxylesterase, EC 3.1.1.1). Esterase is minimally effective at hydrolyzing triglycerides with long-chain esters such as trioleoylglycerol, but has greater activity against monoglycerides and much greater activity against short-chain ester triglycerides such as tributanoylglycerol (25) . The triglyceride substrate of the Ektachem lipase assay has one long-chain (oleic acid) and two short-chain (acetic acid) esters, and may undergo serum esterase-catalyzed hydrolysis to glycerol. ' Nonstandard abbreviations: URL, upper reference limit; GI, gastrointestinal;
and HB, hepatobiliary.
Materials and Methods

Analytical Methods
Lipase and amylase activities in serum were determined with the Ektachem 700 analyzer (Eastman Kodak Co., Rochester, NY) according to the manufacturer's recommended procedures and with use of assay slides obtained from the manufacturer (24, 26 (n = 7); and IV, amylase and lipase sURLs (n = 390). The available medical records (101 of 103) of the patients in groups 1-ifi were studied to determine probable causes for the increased concentrations of serum lipase or amylase. The test combination of serum lipase >URL or serum amylase >URL reportedly has 100% sensitivity for the diagnosis of acute pancreatitis (7, 8, (10) (11) (12) 17) .
Patients were considered to have acute or chronic relapsing pancreatitis only if one or both of the following criteria were met: (a) radiological, ultrasound, or endoscopic retrograde cholangiopancreatographic evidence of pancreatitis; or (b) clinical and laboratory findings consistent with acute pancreatitis for a patient with documented past episodes of pancreatitis (chronic relapsing pancreatitis). Patients with multiple medical problems were assigned a primary diagnostic category according to the following hierarchy: pancreatic disease, if present, was considered the primary diagnosis; second was a disease or problem temporally related to increased serum lipase or amylase; third was a disease or problem most likely to be the cause of the increased serum lipase or amylase; and finally, the most serious medical condition. I reviewed all medical records (except for group IV, above) and assigned a disease category to each patient.
Results
The breakdown of the 101 patients in groups I-Ill is summarized by group in Table 2 . Of the 101 patients with increases in amylase and (or) lipase in serum, the majority (55) had either gastrointestinal (GI) or hepatobiliary (JIB) diseases other than pancreatitis (Table  3) . Confirmed pancreatic diseases of all types were present in only 25 patients. Acute pancreatitis was suspected, but not confirmed, in nine other patients ( Table 2) .
Test performance indicators for acute and chronic relapsing pancreatitis are given in Table 4 . Calculations of test sensitivities, specificities, predictive values, and efficiencies are made with the assumption that patients with normal serum lipase and amylase (group IV) do not have acute or chronic relapsing pancreatitis. Increased serum lipase (groups I and II combined) exhibited 100% sensitivity, 84% specificity, and 85% efficiency for the diagnosis of acute pancreatitis. The test combination of serum lip#{225}->URL and serum amylase >URL (group I) had 72% sensitivity, 96% specificity, and 95% efficiency for the diagnosis of pancreatitis. The test combination of serum lipase threefold greater than the URL and serum amylase >URL (group Ib) achieved the highest efficiency (97%), with 56% sensitivity and 99% specificity. Grouping all pancreatic diseases together decreased the sensitivity, specificity, and efficiency of all test and test combinations (results not shown).
Most (46 of 55, 84%) of the patients classified as having GI or JIB diseases were in group II (serum lipase >URL and serum amylase URL).
Effect of including suspected acute pancreatitis cases
in analysis. Including in the acute pancreatitis category the suspected but unconfirmed cases of acute pancreatitis (noted parenthetically in Table 2 ) alters the test evaluation results ( increased in patients with nonpancreatic disorders, particularly GI and JIB disorders. The Ektachem assay of lipase is almost certainly detecting intestinal lipase activity in these patients, owing to the unique monoleic, diacetic triglyceride substrate used by the Ektachem lipase assay, which in its stereochemical and biochemical properties may be more like a monoglyceride than a naturally occurring triglyceride. Intestinal lipase hydrolyzes monoglycerides more effectively than does pancreatic lipase. The effects of the buffer composition (proprietary formula) and magnesium chloride concentrations on the relative rates of hydrolysis of intestinal and pancreatic lipase in the Ektachem assay are not known, but could also result in greater responsiveness to intestinal lipase. In this study, increased serum lipase activity was three times more likely to be due to GI or HB diseases (53 patients) Table 2 than to acute or chronic relapsing pancreatitis (18 patients). Esterase from rabbit liver was able to hydrolyze 1-oleoyl-2,3-diacetyl glycerol in the Ektachem lipase assay, but at a very slow rate, -400 U of esterase being equivalent to 1 U of lipase activity. If one assumes that the catalytic abilities of human esterase are similar to rabbit esterase, then the esterase effect on the Ektachem lipase assay is not clinically significant. For diagnosing patients with acute abdominal pain compatible with pancreatitis at our institution, I conclude the following:
Good specificity (99%) and efficiency (97%), but mediocre sensitivity (56%), for diagnosing acute pancreatitis are achieved with the test combination of serum lipase threefold greater than URL and serum amylase >URL. For patients in whom this test combination is positive, the post-test probability of acute pancreatitis (67%) is 18-fold greater than the pretest probability (3.7%).
#{149}
The test combination of serum lipase URL and serum amylase tURL is effective in ruling out acute pancreatitis.
#{149} Patients with acute abdominal pain who have serum lipase >URL and serum amylase sURL (group II) are much more likely to have GI or HB disorders (74% post-test probability) other than acute pancreatitis (8.1% post-test probability).
Comparison with other Ektachem lipase and amylase studies. Sensitivity results for the diagnosis of all pancreatic disorders based on serum lipase >URL or serum amylase >URL by the Ektachem assay are similar to those found by Lott et al. (7) (Table 5 ). Lott et a!. studied 175 patients who had serum amylase >URL (diagnostic categories included renal and urinary tract diseases and trauma), and 98 hospitalized patients with no apparent pancreatic disease (control 
